Philip Siberg
Chief Executive Officer
Q1 2025 presentation
Philip Siberg, CEO of Senzime, presents the Q1 report for 2025.
Q1 2025 report presentation
Safeguarding patients during anesthesia and recovery
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Regulatory PR
BULLETIN from annual general meeting in Senzime AB (publ)
Press release
Senzime secures new TetraGraph contract with state-wide university hospital system in southern US
Regulatory PR
Senzime publishes Annual and Sustainability report for 2024
Financial info jan-mar 2025
2025 has started with 94 percent growth
We have strong momentum. Net sales in Q1 increased by 94 percent to SEK 23.5 million. A quarter with record sales, several new important hospital contracts, product launches, and expansion to meet demand. Deliveries of disposable sensors more than doubled once again.
23,5
Net sales, TSEK
94
Net sales, % increase
76
Sales of disposable sensors, % increase
65.9
Gross margin excluding depreciation, %
Subscribe
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.